New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 10, 2014
12:50 EDTARNAArena rallies after partner announces broader coverage for Belviq
Arena Pharmaceuticals (ARNA) partner Eisai announced earlier that it has secured improved patient access of weight loss drug Belviq with CVS Caremark (CVS) and Aetna (AET). CVS Caremark customers have broadened the coverage of Eisai's Belviq, according to Fingertip Formulary, a database of formulary information, the company said. Fingertip Formulary reports that depending on the design of the health plan or employer benefit, eligible CVS Caremark members may have access to Belviq in either a preferred or non-preferred brand position, it added. In addition, Fingertip Formulary states that the number of insured commercial lives in the United States with coverage for Belviq now exceeds 50%. Eisai added that Aetna recently announced that it would offer Belviq as a preferred brand to eligible patients as part of its pilot program to self-insured plan sponsors. Belviq is a registered trademark of Arena Pharmaceuticals (ARNA). Shares of Arena are up 5% to $6.28 in early afternoon trading.
News For ARNA From The Last 14 Days
Check below for free stories on ARNA the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 17, 2014
07:43 EDTARNABofA/Merrill to hold a conference
Subscribe for More Information
September 16, 2014
09:59 EDTARNAArena to need longer studies of 'Bel-phen' combo to judge safety, TheStreet says
Subscribe for More Information
September 11, 2014
12:42 EDTARNAOrexigen falls after FDA requires warnings on Contrave label
Subscribe for More Information
10:59 EDTARNAArena competition picks up after Contrave approval, says Piper Jaffray
Subscribe for More Information
08:01 EDTARNAOrexigen Contrave could have stronger launch than peers, says Wells Fargo
After the FDA approved Orexigen's (OREX) Contrave as a treatment option for chronic weight management, Wells Fargo does not believe the label included any significant surprises. The firm thinks multiple factors increase the chances that Contrave's launch will be stronger than two other weight loss drugs that were launched in recent years by VIVUS and Arena Pharmaceuticals (ARNA). The firm keeps an Outperform rating on Orexigen.
September 9, 2014
12:46 EDTARNANovo Nordisk weight loss drug helped people get thinner, Bloomberg reports
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use